Alnylam Pharmaceuticals Inc

Overview

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes therapeutics based on RNAi interference. The company’s marketed RNAi therapeutics include, Onpattro, is used in treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for treatment of acute hepatic porphyria, Oxlumo developed for treatment of primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in the US, Austria, Belgium, Bermuda, Canada, France, Germany, Italy, Japan, Taiwan, Portugal, Spain, Sweden, the Netherlands, Switzerland, Czech Republic, and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
675 W Kendall St, Cambridge, Massachusetts
Headquarters

United States of America

Contact

1 617 5518200

Website
www.alnylam.com
No of Employees

1,453

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ALNY [NASD]

Revenue (2020)

$493 m

124.4% (2020 vs 2019)
Net Income (2020)

$-858 m

3.2% (2020 vs 2019)
Net Profit Margin

-174 %

56.8% (2020 vs 2019)
Market Cap *

$23,898 m

EPS *

$-7.5

  *Note: Ratios based on the share price as of 6-October-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Alnylam Pharmaceuticals IncF. Hoffmann-La Roche LtdPfizer IncArrowhead Pharmaceuticals Inc
Key Information
Headquarters United States of America Switzerland United States of America United States of America
Headquarter City Cambridge Basel New York Pasadena
Headquarter State/Province Massachusetts - New York California
No. of Employees 1,453 101,465 78,500 98
Entity Type Public Public Public Public

Products & Services

Alnylam researches and develops innovative medicines based on the biology known as RNA interference. Key products and pipeline offered by the company include:

Products
  • Marketed:
  • Onpattro - RNAi therapeutic for treatment of hATTR amyloidosis
  • Givlaari - Acute Hepatic Porphyria
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Onpattro
  • Givlaari
  • Oxlumo
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Tolga Tanguler Chief Commercial Officer Senior Management 2021 - Mr. Tolga Tanguler serves as Chief Commercial Officer at the company since January 2021. Prior to this, he served as...
Yvonne L. Greenstreet President; Chief Operating Officer Senior Management 2020 58 Ms. Yvonne Greenstreet has been the Chief Operating Officer and the President of the company since October 2020. Prior to...
Laurie B. Keating Secretary; Chief Legal Officer; Executive Vice President Senior Management 2019 67 Ms. Laurie B. Keating is the Executive Vice President, Chief Legal Officer and Secretary of the company since 2019. Prior...
Jeff Poulton Chief Financial Officer; Executive Vice President Senior Management 2019 53 Mr. Jeff Poulton has been the Chief Financial Officer and the Executive Vice President of the company since 2019. Prior...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Contracts/Agreements In September, the company and Sharp entered into an agreement for the packaging of Alnylam’s…
2020 Contracts/Agreements In March, the company and Vir Biotechnology announced to extend their partnership to advance RNAi…
2020 Regulatory Approval In February, the company received approval from Brazilian Health Regulatory Agency (ANVISA) to Onpattro (patisiran)…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Alnylam UK Ltd

Address

Braywick Gate, Braywick Rd, Maidenhead
United Kingdom

Telephone

44 1255 444400

Alnylam Germany GmbH

Address

Maximilian Strasse 35a, Munich
Germany

Telephone

49 89 24218118

Alnylam Europe AG

Address

Fritz-Hornschuch-Str. 9, Kulmbach
Germany

Telephone

49 9221 827620

Alnylam Securities Corp

Address

300 3rd Street no.3, Cambridge
United States of America

Telephone

1 617 5518200

Alnylam Italy Srl

Address

Via LePetit 8/10, Milan
Italy

Telephone

39 289 732291

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
03 Dec 2020 Orsini Specialty Enters into Distribution Agreement with Alnylam Pharma Partnership Orsini Healthcare; Alnylam Pharmaceuticals Inc
18 Sep 2020 Alnylam Pharmaceuticals Enters Packaging Agreement with Sharp for RNA interference therapeutics Contract Service Agreement Alnylam Pharmaceuticals Inc Sharp Packaging Services
08 Apr 2019 Alnylam Pharma and Regeneron Pharma to Enter into Partnership Partnership Regeneron Pharmaceuticals Inc; Alnylam Pharmaceuticals Inc
14 Feb 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
14 Feb 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
14 Feb 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

120

Active Jobs

42

Posted

46

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Associate Scientist, In Vitro Alnylam Pharmaceuticals Inc United States
Business Account Executive: Onpattro, Jacksonville, FL Alnylam Pharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar